Pioglitazone antidiabetic drugs

Description Results NMA

all hypoglycemia ∞ [NaN; ∞]

vildagliptin (50 mg b.i.d. (n=295)

vs.

pioglitazone (30 mg daily (n=295)

Sample size: 295/295

Primary endpoint:

FU duration: 52 weeks

death 0.50 [0.05; 5.45]

serious heart failure NaN [NaN; NaN]

stroke 0.00 [0.00; NaN]

myocardial infarction 0.50 [0.05; 5.45]

Death, Myocardial infarction, stroke 0.40 [0.08; 2.03]

Pioglitazone (n=369)

vs.

Rosiglitazone (n=366)

Parallel groups

Sample size: 369/366

Primary endpoint:

FU duration: 24 wk

oral pioglitazone titrated from 15 mg to 45 mg (n=2605)

vs.

placebo (n=2633)

Sample size: 2605/2633

Primary endpoint: all cause death, MI, stroke, ACS, revascularization, amputation (above ankle)

FU duration: 34.5 months

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Death, Myocardial infarction, stroke 0.85 [0.74; 0.98]

serious heart failure 1.39 [1.10; 1.78]

death 0.96 [0.79; 1.17]

stroke 0.81 [0.61; 1.07]

myocardial infarction 0.82 [0.63; 1.06]

CV events 0.90 [0.80; 1.02]

death NaN [NaN; NaN]

serious heart failure NaN [NaN; NaN]

stroke NaN [NaN; NaN]

myocardial infarction 0.00 [0.00; NaN]

Death, Myocardial infarction, stroke 0.00 [0.00; NaN]

death 0.00 [0.00; NaN]

serious heart failure NaN [NaN; NaN]

stroke NaN [NaN; NaN]

myocardial infarction 0.00 [0.00; NaN]

Death, Myocardial infarction, stroke 0.00 [0.00; NaN]

death NaN [NaN; NaN]

serious heart failure NaN [NaN; NaN]

stroke NaN [NaN; NaN]

myocardial infarction 0.24 [0.02; 3.80]

Death, Myocardial infarction, stroke 0.24 [0.02; 3.80]

pioglitazone titrated from 15 mg to 45 mg (n=2605)

vs.

placebo (n=2633)

double blind

Parallel groups

Sample size: 2605/2633

Primary endpoint: cardiovascular events

FU duration: 34.5 mo

Pioglitazone (n=101)

vs.

Placebo (n=96)

Parallel groups

Sample size: 101/96

Primary endpoint:

FU duration: 16 wk

Pioglitazone (n=176)

vs.

Placebo (n=84)

Parallel groups

Sample size: 176/84

Primary endpoint:

FU duration: 24 wk

Pioglitazone (n=329)

vs.

Placebo (n=79)

Parallel groups

Sample size: 329/79

Primary endpoint:

FU duration: 26 wk

CV death 2.99 [0.31; 28.56]

serious heart failure 0.80 [0.22; 2.94]

stroke 0.00 [0.00; NaN]

myocardial infarction 0.50 [0.09; 2.70]

CV events 0.84 [0.38; 1.85]

Death, Myocardial infarction, stroke 0.83 [0.26; 2.69]

death 0.25 [0.02; 2.75]

serious heart failure 0.00 [0.00; NaN]

stroke NaN [NaN; NaN]

myocardial infarction 0.50 [0.07; 3.53]

Death, Myocardial infarction, stroke 0.33 [0.06; 1.98]

death NaN [NaN; NaN]

serious heart failure ∞ [NaN; ∞]

stroke NaN [NaN; NaN]

myocardial infarction ∞ [NaN; ∞]

Death, Myocardial infarction, stroke ∞ [NaN; ∞]

death NaN [NaN; NaN]

serious heart failure ∞ [NaN; ∞]

stroke NaN [NaN; NaN]

myocardial infarction NaN [NaN; NaN]

Death, Myocardial infarction, stroke NaN [NaN; NaN]

death NaN [NaN; NaN]

serious heart failure NaN [NaN; NaN]

stroke NaN [NaN; NaN]

myocardial infarction 0.00 [0.00; NaN]

Death, Myocardial infarction, stroke 0.00 [0.00; NaN]

serious heart failure 2.61 [1.24; 5.50]

death 1.59 [0.67; 3.77]

stroke ∞ [NaN; ∞]

myocardial infarction 2.44 [0.48; 12.48]

Death, Myocardial infarction, stroke 1.47 [0.67; 3.20]

death 0.80 [0.16; 3.99]

serious heart failure 0.00 [0.00; NaN]

stroke 3.01 [0.31; 28.86]

myocardial infarction 1.00 [0.14; 7.10]

Death, Myocardial infarction, stroke 1.14 [0.29; 4.51]

death 0.00 [0.00; NaN]

serious heart failure NaN [NaN; NaN]

stroke NaN [NaN; NaN]

myocardial infarction 1.00 [0.14; 7.04]

Death, Myocardial infarction, stroke 0.50 [0.07; 3.45]

death 1.50 [0.20; 11.24]

serious heart failure 1.50 [0.20; 11.24]

stroke 0.50 [0.05; 5.50]

myocardial infarction 0.75 [0.17; 3.34]

Death, Myocardial infarction, stroke 0.75 [0.18; 3.06]

death 0.75 [0.13; 4.36]

serious heart failure 2.00 [0.15; 26.19]

stroke 0.14 [0.02; 1.16]

myocardial infarction 0.80 [0.22; 2.96]

Death, Myocardial infarction, stroke 0.50 [0.14; 1.83]

death 1.00 [0.11; 8.73]

serious heart failure 0.50 [0.04; 6.55]

stroke 0.66 [0.11; 3.91]

myocardial infarction 4.94 [0.58; 42.02]

Death, Myocardial infarction, stroke 1.33 [0.33; 5.43]

death 1.00 [0.11; 8.73]

serious heart failure ∞ [NaN; ∞]

stroke NaN [NaN; NaN]

myocardial infarction 0.99 [0.14; 6.91]

Death, Myocardial infarction, stroke 1.00 [0.19; 5.29]

death 0.17 [0.02; 1.38]

serious heart failure 1.09 [0.48; 2.45]

stroke 1.11 [0.45; 2.71]

myocardial infarction 0.58 [0.23; 1.47]

Death, Myocardial infarction, stroke 0.72 [0.38; 1.37]

pioglitazone 15 to 45 mg (n=274)

vs.

glimepiride, 1 to 4 mg (n=273)

double blind

Parallel groups

Sample size: 274/273

Primary endpoint: percent atheroma volume

FU duration: 18 months

Pioglitazone + sulfonylurea (n=373)

vs.

Sulfonylurea (n=187)

Parallel groups

Sample size: 373/187

Primary endpoint:

FU duration: 16 wk

Pioglitazone insulin (n=379)

vs.

Placebo + insulin (n=187)

Parallel groups

Sample size: 379/187

Primary endpoint:

FU duration: 16 wk

Pioglitazone + metforminrea (n=168)

vs.

Placebo +metformin (n=160)

Parallel groups

Sample size: 168/160

Primary endpoint:

FU duration: 16 wk

Pioglitazone + insulin (n=110)

vs.

Placebo + insulin (n=112)

Parallel groups

Sample size: 110/112

Primary endpoint:

FU duration: 20 wk

Pioglitazone (n=262)

vs.

Sulfonylurea (n=256)

Parallel groups

Sample size: 262/256

Primary endpoint:

FU duration: 24 wk

Pioglitazone (n=624)

vs.

Sulfonylurea (n=626)

Parallel groups

Sample size: 624/626

Primary endpoint:

FU duration: 52 wk

Pioglitazone (n=251)

vs.

Sulfonylurea (n=251)

Parallel groups

Sample size: 251/251

Primary endpoint:

FU duration: 56 wk

Pioglitazone (n=597)

vs.

Metformin (n=597)

Parallel groups

Sample size: 597/597

Primary endpoint:

FU duration: 52 wk

Pioglitazone + sulfonylurea (n=319)

vs.

Metformin + sulfonylurea (n=320)

Parallel groups

Sample size: 319/320

Primary endpoint:

FU duration: 104 wk

Pioglitazone + metformin (n=317)

vs.

Sulfonylurea + metformin (n=313)

Parallel groups

Sample size: 317/313

Primary endpoint:

FU duration: 104 wk

Pioglitazone (n=151)

vs.

Sulfonylurea (n=149)

Parallel groups

Sample size: 151/149

Primary endpoint:

FU duration: 52 wk

Pioglitazone (n=1051)

vs.

Sulfonylurea (n=1046)

Parallel groups

Sample size: 1051/1046

Primary endpoint:

FU duration: 156 wk